Investigator Initiated Study to Assess the Safety of Combination of CLS-015 With Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive Large B Cell Lymphoma at Lymphodepletion.

NCT07361224 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

12

Enrollment

OTHER_GOV

Sponsor class

Conditions

Large B-Cell Lymphoma (LBCL)

Interventions

DRUG: rhDNase I

Sponsor

Tel-Aviv Sourasky Medical Center